Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090050 · ClinicalTrials.gov registry record · Phase 4
Treximet in the Treatment of Chronic Migraine
A Phase 4 study, sponsored by Cady, Roger, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
NCT01090050: Completed Phase 4 study, sponsored by Cady, Roger, M.D..
NCT01090050 is a Phase 4 study that has completed, run by Cady, Roger, M.D.. The registered enrollment target is 56 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01090050, a Phase 4 study, has completed, sponsored by Cady, Roger, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the hypothesis that use of Treximet in patients with chronic migraine, when used on a short term daily basis and as rescue for break through attacks, will reduce migraine frequency and impact.
Primary Outcome
Comparing the number of migraine headache days during Baseline Period days 1-30 to number of migraine headache days reported in Treatment Period days 91-120 in the Sumatriptan/Naproxen Sodium arm versus (vs.) Naproxen Sodium arm. Percent change=\[(total headache days during Treatment Period Month 3(days 91-120)-total headache days during Baseline(days 1-30)/total headache days during Baseline(days 1-30)\]\*100%)
Interventions
- DRUG Naproxen Sodium
- DRUG Sumatriptan/Naproxen Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
What the finished NCT01090050 record still lists
NCT01090050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Naproxen Sodium is the first listed.
NCT01090050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01090050 about?
NCT01090050 is a clinical study titled "Treximet in the Treatment of Chronic Migraine". This study is being conducted to evaluate the hypothesis that use of Treximet in patients with chronic migraine, when used on a short term daily basis and as rescue for break through attacks, will reduce migraine frequency and impact.
What is the current status of trial NCT01090050?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2010-09. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01090050?
The interventions under investigation include: Naproxen Sodium (DRUG), Sumatriptan/Naproxen Sodium (DRUG).
Who is sponsoring clinical trial NCT01090050?
This trial is sponsored by Cady, Roger, M.D., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01090050's enrollment target sits among peer trials
56 1213th of 2000 higher than 783 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia